Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies

Simon Kaja, Jill D. Hilgenberg, Eric Everett, Scott E. Olitsky, Jim Gossage, Peter Koulen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia and severe, recurrent epistaxis is a common clinical phenotype associated with HHT. An intranasal treatment regime of diluted Avastin™ (Bevacizumab; recombinant humanized anti-vascular epithelial growth factor immunoglobin G1) using apulsatile nasal irrigator has proven efficacious in clinical practice. However, concerns regarding the stability of Avastin™ following dilution and prolonged storage in standard containers used for drug delivery, such as polyethylene bottles, have so far prevented a more widespread clinical use. Compatibility with the preservative benzalkonium chloride was also unknown. Objective: This study aimed at determining, whether dilution, prolonged refrigerated storage and the presence of the preservative benzalkonium chloride - as required for novel Avastin™ formulations - affected the biochemical and electrochemical properties of the drug. Methods: We performed a detailed biochemical and electrochemical analysis of Avastin™, including native and sodium dodecyl sulfate polyacrylamide gel electrophoresis, enzyme-linked immunosorbent assay and isoelectric focusing. Results: We did not detect any evidence of degeneration or aggregation following dilution and prolonged, refrigerated storage or from the presence of benzalkonium chloride. All biochemical and electrochemical properties of Avastin™ after dilution and prolonged, refrigerated storage were undistinguishable from control. Conclusions: Our data provide important insight into the stability of Avastin™ and allow the consideration of novel Avastin™ formulations, including its use in a metered-dose nasal spray for the treatment of HHT and other applications.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalHuman Antibodies
Volume20
Issue number3-4
DOIs
StatePublished - Dec 6 2011

Fingerprint

Hereditary Hemorrhagic Telangiectasia
Nasal Sprays
Polyethylene
Benzalkonium Compounds
Therapeutics
Blood Vessels
Drug Packaging
Epistaxis
Bevacizumab
Isoelectric Focusing
Nose
Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis
Intercellular Signaling Peptides and Proteins
Enzyme-Linked Immunosorbent Assay
Phenotype

Keywords

  • Avastin™
  • Hereditary hemorrhagic telangiectasia
  • bevacizumab
  • dilution
  • storage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. / Kaja, Simon; Hilgenberg, Jill D.; Everett, Eric; Olitsky, Scott E.; Gossage, Jim; Koulen, Peter.

In: Human Antibodies, Vol. 20, No. 3-4, 06.12.2011, p. 95-101.

Research output: Contribution to journalArticle

@article{692a594ef6384786a8f64465b91096b3,
title = "Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies",
abstract = "Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia and severe, recurrent epistaxis is a common clinical phenotype associated with HHT. An intranasal treatment regime of diluted Avastin™ (Bevacizumab; recombinant humanized anti-vascular epithelial growth factor immunoglobin G1) using apulsatile nasal irrigator has proven efficacious in clinical practice. However, concerns regarding the stability of Avastin™ following dilution and prolonged storage in standard containers used for drug delivery, such as polyethylene bottles, have so far prevented a more widespread clinical use. Compatibility with the preservative benzalkonium chloride was also unknown. Objective: This study aimed at determining, whether dilution, prolonged refrigerated storage and the presence of the preservative benzalkonium chloride - as required for novel Avastin™ formulations - affected the biochemical and electrochemical properties of the drug. Methods: We performed a detailed biochemical and electrochemical analysis of Avastin™, including native and sodium dodecyl sulfate polyacrylamide gel electrophoresis, enzyme-linked immunosorbent assay and isoelectric focusing. Results: We did not detect any evidence of degeneration or aggregation following dilution and prolonged, refrigerated storage or from the presence of benzalkonium chloride. All biochemical and electrochemical properties of Avastin™ after dilution and prolonged, refrigerated storage were undistinguishable from control. Conclusions: Our data provide important insight into the stability of Avastin™ and allow the consideration of novel Avastin™ formulations, including its use in a metered-dose nasal spray for the treatment of HHT and other applications.",
keywords = "Avastin™, Hereditary hemorrhagic telangiectasia, bevacizumab, dilution, storage",
author = "Simon Kaja and Hilgenberg, {Jill D.} and Eric Everett and Olitsky, {Scott E.} and Jim Gossage and Peter Koulen",
year = "2011",
month = "12",
day = "6",
doi = "10.3233/HAB-2011-0244",
language = "English (US)",
volume = "20",
pages = "95--101",
journal = "Human Antibodies",
issn = "1093-2607",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies

AU - Kaja, Simon

AU - Hilgenberg, Jill D.

AU - Everett, Eric

AU - Olitsky, Scott E.

AU - Gossage, Jim

AU - Koulen, Peter

PY - 2011/12/6

Y1 - 2011/12/6

N2 - Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia and severe, recurrent epistaxis is a common clinical phenotype associated with HHT. An intranasal treatment regime of diluted Avastin™ (Bevacizumab; recombinant humanized anti-vascular epithelial growth factor immunoglobin G1) using apulsatile nasal irrigator has proven efficacious in clinical practice. However, concerns regarding the stability of Avastin™ following dilution and prolonged storage in standard containers used for drug delivery, such as polyethylene bottles, have so far prevented a more widespread clinical use. Compatibility with the preservative benzalkonium chloride was also unknown. Objective: This study aimed at determining, whether dilution, prolonged refrigerated storage and the presence of the preservative benzalkonium chloride - as required for novel Avastin™ formulations - affected the biochemical and electrochemical properties of the drug. Methods: We performed a detailed biochemical and electrochemical analysis of Avastin™, including native and sodium dodecyl sulfate polyacrylamide gel electrophoresis, enzyme-linked immunosorbent assay and isoelectric focusing. Results: We did not detect any evidence of degeneration or aggregation following dilution and prolonged, refrigerated storage or from the presence of benzalkonium chloride. All biochemical and electrochemical properties of Avastin™ after dilution and prolonged, refrigerated storage were undistinguishable from control. Conclusions: Our data provide important insight into the stability of Avastin™ and allow the consideration of novel Avastin™ formulations, including its use in a metered-dose nasal spray for the treatment of HHT and other applications.

AB - Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia and severe, recurrent epistaxis is a common clinical phenotype associated with HHT. An intranasal treatment regime of diluted Avastin™ (Bevacizumab; recombinant humanized anti-vascular epithelial growth factor immunoglobin G1) using apulsatile nasal irrigator has proven efficacious in clinical practice. However, concerns regarding the stability of Avastin™ following dilution and prolonged storage in standard containers used for drug delivery, such as polyethylene bottles, have so far prevented a more widespread clinical use. Compatibility with the preservative benzalkonium chloride was also unknown. Objective: This study aimed at determining, whether dilution, prolonged refrigerated storage and the presence of the preservative benzalkonium chloride - as required for novel Avastin™ formulations - affected the biochemical and electrochemical properties of the drug. Methods: We performed a detailed biochemical and electrochemical analysis of Avastin™, including native and sodium dodecyl sulfate polyacrylamide gel electrophoresis, enzyme-linked immunosorbent assay and isoelectric focusing. Results: We did not detect any evidence of degeneration or aggregation following dilution and prolonged, refrigerated storage or from the presence of benzalkonium chloride. All biochemical and electrochemical properties of Avastin™ after dilution and prolonged, refrigerated storage were undistinguishable from control. Conclusions: Our data provide important insight into the stability of Avastin™ and allow the consideration of novel Avastin™ formulations, including its use in a metered-dose nasal spray for the treatment of HHT and other applications.

KW - Avastin™

KW - Hereditary hemorrhagic telangiectasia

KW - bevacizumab

KW - dilution

KW - storage

UR - http://www.scopus.com/inward/record.url?scp=82555170648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555170648&partnerID=8YFLogxK

U2 - 10.3233/HAB-2011-0244

DO - 10.3233/HAB-2011-0244

M3 - Article

C2 - 22129679

AN - SCOPUS:82555170648

VL - 20

SP - 95

EP - 101

JO - Human Antibodies

JF - Human Antibodies

SN - 1093-2607

IS - 3-4

ER -